来自官方财务报表的收入、利润与现金流历史。
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹267.2B | ₹225.7B | ₹190.2B | ₹168.8B | — |
| 毛利 | ₹190.6B | ₹159.1B | ₹125.2B | ₹103.2B | — |
| 营业利润（EBIT） | ₹57.9B | ₹59.8B | ₹45.4B | ₹28.5B | — |
| 净利 | ₹50.4B | ₹45.3B | ₹38.6B | ₹19.6B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 ZYDUSLIFE 交互式查看器。 /companies/us/ZYDUSLIFE
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms